[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643820":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":25,"responsibleParty":38,"collaborators":25,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":25,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":25,"overallStatus":64,"whyStopped":25,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":25},{"fullName":5,"class":6},"Shanghai Public Health Clinical Center","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TLE group","ACTIVE_COMPARATOR","Antiretroviral therapy is initiated 14 days after participants receive anti-tuberculosis treatment consisting of rifampicin and isoniazid. The regimen is Efavirenz 400 mg, Lamivudine 300 mg and Tenofovir Disoproxil Fumarate 300 mg, one tablet of each taken once daily.",[13],"Drug: Tenofovir, Lamivudine and Efavirenz Disoproxil Fumarate Tablets",{"label":15,"type":16,"description":17,"interventionNames":18},"ALT group","EXPERIMENTAL","Antiretroviral therapy is initiated 14 days after participants receive anti-tuberculosis treatment with rifampicin and isoniazid. The regimen is Ainuovirine 150mg, Lamivudine 300mg and Tenofovir 300mg, one tablet each time, once daily.",[19],"Drug: Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets",[21,26],{"type":22,"name":23,"description":17,"armGroupLabels":24,"otherNames":25},"DRUG","Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets",[15],null,{"type":22,"name":27,"description":11,"armGroupLabels":28,"otherNames":25},"Tenofovir, Lamivudine and Efavirenz Disoproxil Fumarate Tablets",[9],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Jun Chen","CONTACT","021-37990333","chenjun@shaphc.org",{"name":36,"role":32,"phone":33,"phoneExt":25,"email":37},"Ling Gu","guling@shaphc.org",{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Jun Chen, MD","Chief Physician","100643820","phase-4-comparative-trial-between-ainuovirineanvlamivudine3tctenofovirtdf-and-efavirenzefvlamivudinetenofovir-regimens-100643820",false,"NCT07631897","Comparative Trial Between Ainuovirine(ANV)\u002FLamivudine(3TC)\u002FTenofovir(TDF) and Efavirenz(EFV)\u002FLamivudine\u002FTenofovir Regimens","Comparative Study on Antiviral Efficacy and Safety of Ainuovirine\u002FLamivudine\u002FTenofovir Versus Efavirenz\u002FLamivudine\u002FTenofovir Regimen in HIV Patients With Active Tuberculosis Infection: A Two-stage Prospective Multicenter Clinical Study","ALT VS TLE","Inclusion Criteria:\n\n* Aged between 18 and 65 years;\n* Body weight ≥ 40 kg with BMI ranging from 18.5 to 30 kg\u002Fm²;\n* Treatment-naïve patients with HIV-1 infection who are planned to initiate antiretroviral therapy;\n* Diagnosed with active Mycobacterium tuberculosis infection and receiving anti-tuberculosis regimen containing rifampicin and isoniazid;\n* CD4⁺ T cell count ≥ 25 cells\u002FμL;\n* HIV RNA viral load \\\u003C 500,000 copies\u002FmL;\n* Subjects who can fully understand the nature, methods and potential adverse reactions of this trial, comply with the requirements stated in the informed consent form, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Subjects with allergic constitution or a history of allergy to the study drugs and excipients;\n* Those with a history of drug addiction, substance abuse, or chronic alcoholism;\n* Pregnant or lactating women; women of childbearing potential who cannot adopt effective contraceptive measures (e.g., contraceptive diaphragm, condom, intrauterine device, partner vasectomy), or whose sexual partners fail to implement effective contraception;\n* Subjects who have used drugs with moderate to high drug drug interaction potential with the study drugs (excluding anti tuberculosis drugs) within 2 weeks prior to formal enrollment and ART initiation (only applicable to the pre trial phase);\n* Those who are unable to receive oral anti tuberculosis treatment during antiretroviral therapy;\n* Subjects with baseline drug resistance test results showing resistance to NNRTIs, 3TC or TDF;\n* Those with resistance to one or more anti tuberculosis drugs;\n* Subjects diagnosed or tentatively diagnosed with tuberculous meningitis;\n* Patients complicated with other severe opportunistic infections besides Mycobacterium tuberculosis infection;\n* Abnormal liver function: alanine transaminase (ALT)\u002Faspartate transaminase (AST) \\> 3×ULN with clinical symptoms, or \\> 5×ULN without symptoms; total bilirubin (TBil) \\> 2×ULN;\n* Impaired renal function: estimated glomerular filtration rate (eGFR) calculated by the CKD EPI formula \\\u003C 60 mL\u002Fmin\u002F1.73 m²;\n* Subjects complicated with tumors, severe neurological or psychiatric diseases, metabolic disorders, gastrointestinal diseases or other comorbidities that, in the investigator's judgment, may affect their participation and completion of the study;\n* Any other conditions deemed inappropriate for enrollment by the investigator.","ALL","18 Years","65 Years",{"count":54,"type":55},60,"ESTIMATED","INTERVENTIONAL",[58],"PHASE4","This is a prospective, multicenter, open-label, parallel-controlled study. The primary objective is to prospectively explore and compare the virological efficacy of Ainuovirine\u002FLamivudine\u002FTenofovir and Efavirenz\u002FLamivudine\u002FTenofovir regimens combined with rifampicin and isoniazid-based anti-tuberculosis therapy in HIV-infected patients with active tuberculosis.\n\nParticipants are divided into two groups to compare the virological suppression rate and immunological efficacy between the two antiretroviral regimens. All subjects will receive continuous antiretroviral medication and anti-tuberculosis drugs under medical supervision throughout the study.",[61,62,63],"HIV","Art Therapy","TB - Tuberculosis","NOT_YET_RECRUITING","2026-06-01",{"date":67,"type":68},"2026-06-08","ACTUAL",{"date":70,"type":55},"2026-06",{"date":72,"type":55},"2028-12",{"name":5,"class":6}]